Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research note published on Friday,RTT News reports. The brokerage currently has a $11.00 price target on the stock.

A number of other research firms have also commented on CATX. UBS Group assumed coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Finally, Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.14.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $4.01 on Friday. Perspective Therapeutics has a 12-month low of $2.70 and a 12-month high of $19.05. The company has a 50-day simple moving average of $3.68 and a two-hundred day simple moving average of $9.75.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21). The firm had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. Sell-side analysts expect that Perspective Therapeutics will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other Perspective Therapeutics news, Director Heidi Henson bought 25,975 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was acquired at an average price of $3.85 per share, with a total value of $100,003.75. Following the transaction, the director now owns 25,975 shares in the company, valued at $100,003.75. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Johan M. Spoor bought 8,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was bought at an average cost of $3.77 per share, with a total value of $30,160.00. Following the transaction, the chief executive officer now owns 36,257 shares in the company, valued at $136,688.89. This trade represents a 28.31 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company boosted its holdings in Perspective Therapeutics by 8.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock worth $274,000 after buying an additional 1,672 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Perspective Therapeutics by 5.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock worth $783,000 after acquiring an additional 3,211 shares during the period. US Bancorp DE grew its position in shares of Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. nVerses Capital LLC bought a new stake in Perspective Therapeutics during the 3rd quarter valued at approximately $57,000. Finally, JPMorgan Chase & Co. lifted its holdings in Perspective Therapeutics by 24.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company’s stock worth $333,000 after purchasing an additional 4,844 shares in the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.